HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that it will present three month follow-up data from the first patient to receive PLX-PAD at both the 1st Annual Conference of the German-Israeli Life Science Committee at the Life Science Center in Düsseldorf, Germany and at the DigestScience Congress in Lille, France. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
